Validation of the BEAMER Model – factors influencing adherence behaviour
The BEAMER project is an Innovation Medicine Initiative (IMI) funded public-private partnership that focuses on [...]
Read More
22
Jul
Jul
Understanding Duchenne: The Role of World Duchenne Organization in BEAMER
(From left to right: Suzie-Ann Bakker and Dimitrios Athanasiou, World Duchenne Organization) The role [...]
Read More
03
May
May
An analysis of medication adherence through Electronic Health Records (EHR) data
As researchers in Pharmacoepidemiology and Pharmacovigilance focused on studying the use, adherence, effectiveness and safety [...]
Read More
29
Nov
Nov
“Lighting The Way” Blog Series #6: Adherence and Effiency
Each month, we convene several partner organisations from the BEAMER project to discuss one of [...]
Read More
02
Oct
Oct
“Lighting The Way” Blog Series #5: Adherence and Equity
Each month, we convene several partner organisations from the BEAMER project to discuss one of [...]
Read More
10
Jul
Jul
“Lighting The Way” Blog Series #4: Adherence and Effectiveness
Each month, we convene several partner organisations from the BEAMER project to discuss one of [...]
Read More
19
May
May
“Lighting The Way” Blog Series #3: Adherence and Timeliness
Each month, we convene several partner organisations from the BEAMER project to discuss one of [...]
Read More
22
Mar
Mar
“Lighting The Way” Blog Series #2: Adherence and Patient-Centredness
Each month, we gather a few partner organisations from the BEAMER project to discuss one [...]
Read More
20
Feb
Feb
Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.
Disclaimer:
Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
